{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:30Z","timestamp":1793042130490,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The standard care of glioblastomas (GBM) confers limited survival benefit for patients due to the rapid tumor recurrence. Targeting tumor-associated macrophages\/microglia via colony-stimulating factor 1 receptor (CSF-1R) inhibition is potentially effective in suppressing GBM recurrence. However, clinical trials of CSF-1R inhibitors failed to achieve their goal due to GBM resistance to anti-CSF-1R therapy. Here, we identified and verified key resistance mechanisms of anti-CSF-1R therapy by translatome profiling-combined analyses. To solve above problem, we have established a highly stable and refractory mouse G422\n                    <jats:sup>TN<\/jats:sup>\n                    -GBM model, in which temozolomide (TMZ) is the most effective monotherapy but can only slightly extend animal survival. To identify effective resistance mechanism of anti-CSF1R therapy in GBM, we first apply the Translating ribosome affinity purification (TRAP) RNA-sequencing techniques in GBM tissues, which have previously used in neuroscience. TRAP-seq identified oxidative phosphorylation\/glycolysis as anti-CSF1R therapy resistance mechanism, and it\u2019s combined with Cancer Therapeutics Response Portal (CTRP) identified piperlongumine (PL) or vorinostat (SAHA) as targeting drugs. PL or SAHA enhanced PLX3397 efficacy by reversing oxidative phosphorylation\/glycolysis dysregulation in vitro and in vivo. The triple combination of PLX3397, TMZ, and PL\/SAHA significantly improved survival in G422\n                    <jats:sup>TN<\/jats:sup>\n                    -GBM mice. In conclusion, targeting oxidative phosphorylation\/glycolysis by PL or SAHA prominently improves therapeutic efficacy of PLX3397\u2009+\u2009TMZ in GBM, which deserves priority for clinical trials. Our study also reveals that translatome profiling is efficient for uncovering drug-resistant targets.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08288-3","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:56:11Z","timestamp":1765335371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification and targeting oxidative phosphorylation\/glycolysis to overcome anti-CSF-1R therapy resistance in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6504-1695","authenticated-orcid":false,"given":"Cheng","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-1046","authenticated-orcid":false,"given":"Ruoqiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2673-2977","authenticated-orcid":false,"given":"Xiao Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"8288_CR1","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/brainsci13111602","volume":"13","author":"E Begagi\u0107","year":"2023","unstructured":"Begagi\u0107 E, Pugonja R, Be\u010duli\u0107 H, \u010celikovi\u0107 A, Tandir Lihi\u0107 L, Kadi\u0107 Vukas S, et al. Molecular targeted therapies in glioblastoma multiforme: a systematic overview of global trends and findings. Brain Sci. 2023;13:1602.","journal-title":"Brain Sci"},{"key":"8288_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. a systematic review. J Clin Neurosci. 2018;54:7\u201313.","journal-title":"J Clin Neurosci"},{"key":"8288_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.5603\/RPOR.a2022.0113","volume":"27","author":"S Mohammed","year":"2022","unstructured":"Mohammed S, Dinesan M, Ajayakumar T. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Parct Oncol Radiother. 2022;27:1026\u201336.","journal-title":"Rep Parct Oncol Radiother"},{"key":"8288_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1249366","volume":"10","author":"B Fekete","year":"2023","unstructured":"Fekete B, Werlenius K, Tisell M, Pivodic A, Smits A, Jakola AS, et al. What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome. Front Surg. 2023;10:1249366.","journal-title":"Front Surg"},{"key":"8288_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05301-9","volume":"22","author":"J White","year":"2024","unstructured":"White J, White MPJ, Wickremesekera A, Peng L, Gray C. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med. 2024;22:540.","journal-title":"J Transl Med"},{"key":"8288_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780.","journal-title":"Pharmacol Res"},{"key":"8288_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024921","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhong H, Liang X, Ni S. Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: navigating the clinical and translational landscape. Front Immunol. 2022;13:1024921.","journal-title":"Front Immunol"},{"key":"8288_CR8","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.3390\/cancers14194910","volume":"14","author":"X Liu","year":"2022","unstructured":"Liu X, Huang Y, Qi Y, Wu S, Hu F, Wang J, et al. The GBM tumor microenvironment as a modulator of therapy response: ADAM8 causes tumor infiltration of tams through HB-EGF\/EGFR-mediated CCL2 expression and overcomes TMZ chemosensitization in glioblastoma. Cancers. 2022;14:4910.","journal-title":"Cancers"},{"key":"8288_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/BST20150245","volume":"44","author":"D Achkova","year":"2016","unstructured":"Achkova D, Maher J. Role of the colony-stimulating factor (CSF)\/CSF-1 receptor axis in cancer. Biochem Soc Trans. 2016;44:333\u201341.","journal-title":"Biochem Soc Trans"},{"key":"8288_CR10","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1021\/acs.jmedchem.7b00873","volume":"61","author":"MI El-Gamal","year":"2018","unstructured":"El-Gamal MI, Al-Ameen SK, Al-Koumi DM, Hamad MG, Jalal NA, Oh CH. Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors. J Med Chem. 2018;61:5450\u201366.","journal-title":"J Med Chem"},{"key":"8288_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","volume":"23","author":"CH Ries","year":"2015","unstructured":"Ries CH, Hoves S, Cannarile MA, R\u00fcttinger D. CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol. 2015;23:45\u201351.","journal-title":"Curr Opin Pharmacol"},{"key":"8288_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114884","volume":"245","author":"J Wen","year":"2023","unstructured":"Wen J, Wang S, Guo R, Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem. 2023;245:114884.","journal-title":"Eur J Med Chem"},{"key":"8288_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/DDDT.S253232","volume":"14","author":"B Benner","year":"2020","unstructured":"Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, et al. Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development. Drug Des Dev Ther. 2020;14:1693\u2013704.","journal-title":"Drug Des Dev Ther"},{"key":"8288_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5:53.","journal-title":"J Immunother Cancer"},{"key":"8288_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101514","volume":"54","author":"P Ordentlich","year":"2021","unstructured":"Ordentlich P. Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. Semin Immunol. 2021;54:101514.","journal-title":"Semin Immunol"},{"key":"8288_CR16","volume":"6","author":"JS Mendez","year":"2024","unstructured":"Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, et al. Phase 1b\/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2024;6:vdae202.","journal-title":"Neurooncol Adv"},{"key":"8288_CR17","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1038\/onc.2017.261","volume":"36","author":"D Yan","year":"2017","unstructured":"Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, et al. Inhibition of colony-stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. 2017;36:6049\u201358.","journal-title":"Oncogene"},{"key":"8288_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264\u201372.","journal-title":"Nat Med"},{"key":"8288_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352:aad3018.","journal-title":"Science"},{"key":"8288_CR20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220857","volume":"220","author":"JP Chadarevian","year":"2023","unstructured":"Chadarevian JP, Lombroso SI, Peet GC, Hasselmann J, Tu C, Marzan DE, et al. Engineering an inhibitor-resistant human CSF1R variant for microglia replacement. J Exp Med. 2023;220:e20220857.","journal-title":"J Exp Med"},{"key":"8288_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2021.06.072","volume":"569","author":"F Liu","year":"2021","unstructured":"Liu F, Xu XH, Li CY, Zhang TT, Yin SL, Liu GQ, et al. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt\/PD-L1\/vimentin signaling. Biochem Biophys Res Commun. 2021;569:1\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"8288_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.226","volume":"10","author":"F Liu","year":"2020","unstructured":"Liu F, Xu X, Li C, Li C, Li Y, Yin S, et al. Mannose synergizes with chemoradiotherapy to cure cancer via metabolically targeting HIF-1 in a novel triple-negative glioblastoma mouse model. Clin Transl Med. 2020;10:e226.","journal-title":"Clin Transl Med"},{"key":"8288_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-023-02686-1","volume":"42","author":"F Liu","year":"2023","unstructured":"Liu F, Zhou Q, Jiang HF, Zhang TT, Miao C, Xu XH, et al. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8-T cell immunity. J Exp Clin Cancer Res. 2023;42:118.","journal-title":"J Exp Clin Cancer Res"},{"key":"8288_CR24","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","volume":"1864","author":"XY Qiu","year":"2018","unstructured":"Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1754\u201369.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8288_CR25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fonc.2019.01347","volume":"9","author":"RQ Chen","year":"2019","unstructured":"Chen RQ, Xu XH, Liu F, Li CY, Li YJ, Li XR, et al. The binding of PD-L1 and Akt facilitates glioma cell invasion upon starvation via Akt\/Autophagy\/F-actin signaling. Front Oncol. 2019;9:1347.","journal-title":"Front Oncol"},{"key":"8288_CR26","doi-asserted-by":"crossref","unstructured":"Gao PP, Jiang HF, Du YW, Shu Y, Wan YW, Yin EZ, et al. CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12(+) microglia transformation. Acta Pharmacol Sin. 2025;46:3053\u20133070.","DOI":"10.1038\/s41401-025-01585-9"},{"key":"8288_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165:535\u201350.","journal-title":"Cell"},{"key":"8288_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227\u201332.","journal-title":"Nat Rev Genet"},{"key":"8288_CR29","doi-asserted-by":"publisher","first-page":"22130","DOI":"10.1002\/cam4.6719","volume":"12","author":"DM Bravo-Estupinan","year":"2023","unstructured":"Bravo-Estupinan DM, Aguilar-Guerrero K, Quiros S, Acon M-S, Marin-Muller C, Ibanez-Hernandez M, et al. Gene dosage compensation: origins, criteria to identify compensated genes, and mechanisms including sensor loops as an emerging systems-level property in cancer. Cancer Med. 2023;12:22130\u201355.","journal-title":"Cancer Med"},{"key":"8288_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcae024","volume":"6","author":"\u00c1C Rom\u00e1n","year":"2024","unstructured":"Rom\u00e1n \u00c1C, Ben\u00edtez DA, D\u00edaz-Pizarro A, Del Valle-Del Pino N, Olivera-G\u00f3mez M, Cumplido-Laso G, et al. Next generation sequencing technologies to address aberrant mRNA translation in cancer. NAR Cancer. 2024;6:zcae024.","journal-title":"NAR Cancer"},{"key":"8288_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10795-9","volume":"10","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Hu DX, He F, Li CY, Qi GJ, Cai HW, et al. Locus coeruleus-CA1 projections are involved in chronic depressive stress-induced hippocampal vulnerability to transient global ischaemia. Nat Commun. 2019;10:2942.","journal-title":"Nat Commun"},{"key":"8288_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31773-8","volume":"13","author":"I Takeda","year":"2022","unstructured":"Takeda I, Yoshihara K, Cheung DL, Kobayashi T, Agetsuma M, Tsuda M, et al. Controlled activation of cortical astrocytes modulates neuropathic pain-like behaviour. Nat Commun. 2022;13:4100.","journal-title":"Nat Commun"},{"key":"8288_CR33","first-page":"584","volume":"24","author":"R Rao","year":"2022","unstructured":"Rao R, Han R, Ogurek S, Xue C, Wu L, Zhang L, et al. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition. Neurooncol. 2022;24:584\u201397.","journal-title":"Neurooncol"},{"key":"8288_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.787307","volume":"12","author":"C Barca","year":"2021","unstructured":"Barca C, Foray C, Hermann S, Herrlinger U, Remory I, Laoui D, et al. The colony-stimulating factor-1 receptor (CSF-1R)-mediated regulation of microglia\/macrophages as a target for neurological disorders (glioma, stroke). Front Immunol. 2021;12:787307.","journal-title":"Front Immunol"},{"key":"8288_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13046-021-02135-x","volume":"40","author":"R Vengoji","year":"2021","unstructured":"Vengoji R, Atri P, Macha MA, Seshacharyulu P, Perumal N, Mallya K, et al. Differential gene expression-based connectivity mapping identified novel drug candidate and improved temozolomide efficacy for glioblastoma. J Exp Clin Cancer Res. 2021;40:335.","journal-title":"J Exp Clin Cancer Res"},{"key":"8288_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.96257.3","volume":"13","author":"D Algranati","year":"2024","unstructured":"Algranati D, Oren R, Dassa B, Fellus-Alyagor L, Plotnikov A, Barr H, et al. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas. Elife. 2024;13:RP96257.","journal-title":"Elife"},{"key":"8288_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20:710\u201320.","journal-title":"Neoplasia"},{"key":"8288_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0260-8","volume":"9","author":"XX Xiong","year":"2018","unstructured":"Xiong XX, Pan F, Chen RQ, Hu DX, Qiu XY, Li CY, et al. Neuroglobin boosts axon regeneration during ischemic reperfusion via p38 binding and activation depending on oxygen signal. Cell Death Dis. 2018;9:163.","journal-title":"Cell Death Dis"},{"key":"8288_CR39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/nprot.2014.085","volume":"9","author":"M Heiman","year":"2014","unstructured":"Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N. Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). Nat Protoc. 2014;9:1282\u201391.","journal-title":"Nat Protoc"},{"key":"8288_CR40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1021\/acscentsci.1c00070","volume":"7","author":"J Conde","year":"2021","unstructured":"Conde J, Pumroy RA, Baker C, Rodrigues T, Guerreiro A, Sousa BB, et al. Allosteric antagonist modulation of TRPV2 by piperlongumine impairs glioblastoma progression. ACS Cent Sci. 2021;7:868\u201381.","journal-title":"ACS Cent Sci"},{"key":"8288_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5:517\u201331.","journal-title":"Nat Cancer"},{"key":"8288_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"8288_CR43","doi-asserted-by":"crossref","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;24:123\u201347.","DOI":"10.1146\/annurev-pathmechdis-012418-012718"},{"key":"8288_CR44","first-page":"557","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony-stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation early phase clinical trials consortium phase II study. Neurooncol. 2016;18:557\u201364.","journal-title":"Neurooncol"},{"key":"8288_CR45","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","volume":"26","author":"C Murga-Zamalloa","year":"2020","unstructured":"Murga-Zamalloa C, Rolland DCM, Polk A, Wolfe A, Dewar H, Chowdhury P, et al. Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-Cell lymphoma viability. Clin Cancer Res. 2020;26:690\u2013703.","journal-title":"Clin Cancer Res"},{"key":"8288_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/iovs.62.3.37","volume":"62","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zeng J, Tu Y, Li L, Du S, Zhu L, et al. CSF1\/CSF1R-mediated crosstalk between choroidal vascular endothelial cells and macrophages promotes choroidal neovascularization. Investig Ophthalmol Vis Sci. 2021;62:37.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"8288_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fonc.2012.00186","volume":"2","author":"K Yoshimoto","year":"2012","unstructured":"Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, et al. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol. 2012;2:186.","journal-title":"Front Oncol"},{"key":"8288_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2119\/molmed.2011.00217","volume":"18","author":"SJ Coniglio","year":"2012","unstructured":"Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony-stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 2012;18:519\u201327.","journal-title":"Mol Med"},{"key":"8288_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.817191","volume":"9","author":"J Corbacho","year":"2022","unstructured":"Corbacho J, Sanabria-Reinoso E, Buono L, Fern\u00e1ndez-Mi\u00f1an A, Mart\u00ednez-Morales JR. Trap-TRAP, a versatile tool for tissue-specific translatomics in zebrafish. Front Cell Dev Biol. 2022;9:817191.","journal-title":"Front Cell Dev Biol"},{"key":"8288_CR50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.90713.3","volume":"12","author":"T Ichinose","year":"2024","unstructured":"Ichinose T, Kondo S, Kanno M, Shichino Y, Mito M, Iwasaki S, et al. Translational regulation enhances distinction of cell types in the nervous system. Elife. 2024;12:RP90713.","journal-title":"Elife"},{"key":"8288_CR51","doi-asserted-by":"publisher","first-page":"707","DOI":"10.7150\/thno.101658","volume":"15","author":"C Li","year":"2025","unstructured":"Li C, Miao C, Ge Y, Wu J, Gao P, Yin S, et al. A molecularly distinct cell type in the midbrain regulates intermale aggression behaviors in mice. Theranostics. 2025;15:707\u201325.","journal-title":"Theranostics"},{"key":"8288_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/path.4192","volume":"230","author":"M Sielska","year":"2013","unstructured":"Sielska M, Przanowski P, Wylot B, Gabrusiewicz K, Maleszewska M, Kijewska M, et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J Pathol. 2013;230:310\u201321.","journal-title":"J Pathol"},{"key":"8288_CR53","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352:997\u20131003.","journal-title":"New Engl J Med"},{"key":"8288_CR54","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3892\/ijo_00000621","volume":"36","author":"A Yoshino","year":"2010","unstructured":"Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, et al. Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 2010;36:1367\u201377.","journal-title":"Int J Oncol"},{"key":"8288_CR55","first-page":"797","volume":"18","author":"JH Stafford","year":"2016","unstructured":"Stafford JH, Hirai T, Deng L, Chernikova SB, Urata K, West BL, et al. Colony-stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neurooncol. 2016;18:797\u2013806.","journal-title":"Neurooncol"},{"key":"8288_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"8288_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474\u20138.","journal-title":"Nature"},{"key":"8288_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","volume":"12","author":"M Li","year":"2022","unstructured":"Li M, He L, Zhu J, Zhang P, Liang S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 2022;12:85.","journal-title":"Cell Biosci"},{"key":"8288_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07399-1","volume":"16","author":"D Zheng","year":"2025","unstructured":"Zheng D, Deng Y, Deng L, He Z, Sun X, Gong Y, et al. CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. Cell Death Dis. 2025;16:68.","journal-title":"Cell Death Dis"},{"key":"8288_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2013.06.042","volume":"437","author":"JM Liu","year":"2013","unstructured":"Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, et al. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation-dependent JNK and p38 activation. Biochem Biophys Res Commun. 2013;437:87\u201393.","journal-title":"Biochem Biophys Res Commun"},{"key":"8288_CR61","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1172\/JCI129049","volume":"130","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Investig. 2020;130:3699\u2013716.","journal-title":"J Clin Investig"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08288-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08288-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:03:28Z","timestamp":1769184208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08288-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8288"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08288-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"(a) All animal handling and experimental procedures were conducted in accordance with the National Institutes of Health (NIH) and ARRIVE guidelines. (b) All experimental protocols were approved by the Institutional Animal Care and Use Committee at HUST ([2024] IACUC Number: 4270). (c) This study did not involve human subjects and does not contain images derived from human research participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"84"}}